Targeting the kidney with AAV is notoriously difficult compared to the liver or eye. The kidney’s complex filtration system and the presence of the glomerular filtration barrier (GFB) make it hard for vectors to reach specific segments like the podocytes or the tubular epithelium.

Quick Legend: Administration Routes

• IV (Intravenous): Systemic delivery. Most AAVs get “trapped” in the liver before reaching the kidney, and those that do often cannot cross the basement membrane.
• Rend (Renal Artery Injection): Direct injection into the kidney’s blood supply. Increases local concentration but is surgically invasive.
• Retro (Retrograde Ureteral): Injection via the ureter (backward flow). Best for targeting the collecting ducts and tubular epithelium, bypassing the blood-flow barriers.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV9	Podocytes, Glomerular Cells	IV / Renal Artery	The Best Natural Performer. • One of the few natural serotypes capable of transducing the kidney at a measurable level systemically. • Primarily targets the glomerulus (podocytes) but efficiency is still relatively low compared to other organs.
AAV2	Tubular Epithelium	Retrograde	Localized Efficiency. • Very poor via IV due to liver sequestration and poor penetration. • If delivered via the ureter (retrograde), it can effectively reach the renal tubular cells.
AAV1 / AAV6	Vascular Endothelium	IV	Mostly restricted to the renal vasculature; they rarely penetrate into the deeper functional units (nephrons) from the bloodstream.
AAV8	Inefficient in Kidney	N/A	While excellent for the liver, AAV8 shows almost negligible transduction in the kidney compared to AAV9.

---

2. Engineered & Synthetic Capsids

Because natural AAVs are poor kidney vectors, engineering is the primary focus for renal gene therapy.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV-Anc80	Tubular Cells, Podocytes	IV / Renal Artery	Ancestral Potency. • A synthetic ancestral capsid that significantly outperforms AAV9 and AAV8 in reaching the renal cortex and tubules. • High stability and lower pre-existing immunity in humans.
AAV-PHP.B	Glomerular Endothelium	IV	Originally designed for the Blood-Brain Barrier (BBB), this capsid also shows enhanced ability to transduce renal vascular and glomerular cells compared to wild-type AAV9.
AAV-DJ	Tubular Cells	Retrograde	Highly efficient in vitro; in vivo it performs well if delivered directly to the renal pelvis, but like others, it fails to hit the kidney effectively via IV.
AAV-B1	Multiple Nephron Segments	IV	A bioengineered variant that shows broad transduction across the kidney, including the tubules, which are usually shielded from systemic vectors.

---

3. Tropism by Segment

If you are targeting a specific part of the nephron, start here:

• Podocytes (Glomerulus): AAV9 (Natural) or AAV-Anc80 (Synthetic).
• Proximal/Distal Tubules: AAV-Anc80 or AAV-B1 (via IV); AAV2 (via Retrograde).
• Collecting Ducts: AAV2 or AAV6 (best reached via Retrograde/Ureteral delivery).
• Renal Vasculature: AAV1 or AAV-PHP.B.

Critical Factor: The Filtration Barrier

The kidney is a biological sieve. To get a gene into a tubular cell from the blood, the AAV must pass through:

1. The fenestrated endothelium.
2. The glomerular basement membrane.
3. The slit diaphragms of podocytes.

The “Liver Problem” in Kidney Research:

Because the kidney is so difficult to target, researchers often use Kidney-Specific Promoters (like Nphs1 for podocytes or Ksp-cadherin for tubules). Even if the AAV ends up in the liver (which it will), the therapeutic protein is only produced in the kidney cells.